Cybin (FRA:R7E1) Debt-to-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Cybin Debt-to-Asset?

Cybin's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.22 Mil. Cybin's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.03 Mil. Cybin's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €88.67 Mil. Cybin's debt to asset for the quarter that ended in Dec. 2023 was 0.00.

Cybin Debt-to-Asset Historical Data

The historical data trend for Cybin's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cybin Debt-to-Asset Chart

Cybin Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Debt-to-Asset

Cybin Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Cybin's Debt-to-Asset

For the Biotechnology subindustry, Cybin's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cybin's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cybin's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cybin's Debt-to-Asset falls into.

Cybin Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cybin's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	36.79
	=	0.00

Cybin's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.221	+	0.029)	/	88.668
	=	0.00

Cybin (FRA:R7E1) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Cybin Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Cybin's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cybin (FRA:R7E1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (FRA:R7E1) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

CYBN:USA CYBN:Canada

Address

100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9

Website

https://www.cybin.com

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions.

Cybin (FRA:R7E1) Headlines

No Headlines